The CD19-ReTARGTPR approach appears to be particularly promising for CD19-expressing leukemia, given that approximately 72% of CLL patients are CMV-seropositive and maintain functional anti-CMV T cell responses, while generalized anergy is often observed in their CD8pos T cell compartments [8,23]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.